# Maternal Vaccination Strategy Against Klebsiella Infections in Newborns Researchers test a new maternal vaccine in mice to prevent lethal newborn sepsis. - **Source:** [Earth.com](https://www.earth.com) - **Published:** 2026-11-12 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/1a8055f6-a7e6-41a8-b6ac-4c098ec347cd ## Newborn Vulnerability to Sepsis Newborns possess minimal immune defenses, making them highly susceptible to Klebsiella pneumoniae. This bacterium causes widespread sepsis in low- and middle-income countries, where 85 percent of strains exhibit resistance to common antibiotics. With no existing vaccine, researchers are exploring maternal immunization as a strategy to protect infants during their most vulnerable period. ## Maternal Antibody Transfer Mechanism The experimental vaccine targets the sugar coat of Klebsiella cells, specifically types K1 and K2. By vaccinating mother mice, researchers observed that protective antibodies were successfully transferred to pups through the placenta and breast milk. These antibodies remained detectable in the offspring for six weeks, providing a window of passive immunity. ## Experimental Survival Rate Results In controlled tests, pups from vaccinated mothers showed significantly higher survival rates when exposed to lethal doses of bacteria. Over 80 percent of pups from vaccinated mothers survived K1 strain infections, whereas nearly all pups from unvaccinated mothers died. Similar protective effects were observed against the K2 strain, confirming the vaccine's potential efficacy. ## St. Louis Startup Collaboration The vaccine candidates were developed by Omniose, a St. Louis-based startup. The research team utilized a carrier protein to help the immune system recognize the bacterial sugar coat. Four authors of the study hold a financial stake in the company, highlighting the intersection of academic research and private sector biotechnology development. ## Dosing Schedule and Practicality Researchers tested two-dose and three-dose regimens in mice, finding that both schedules produced similar antibody levels by day 21. This finding is significant for human application, as ensuring multiple follow-up visits during pregnancy can be challenging. The study suggests that simplified vaccination schedules could still provide robust protection for the developing infant. ## Limitations of Mouse Models The study acknowledges several gaps between mouse models and human clinical reality. Most human sepsis cases occur in the first week of life, whereas the mice were infected at two weeks. Additionally, the study used full-term mice, while many human infections involve premature infants who may not receive sufficient maternal antibodies in time. ## Future Clinical Development Path David A. Rosen of WashU Medicine emphasizes that human trials are several steps away. Future efforts will focus on selecting the optimal target mix and ensuring safety in non-pregnant populations before moving to pregnant women. A large-scale phase 3 trial would eventually require international cooperation and support from major global health funders. ## Broader Implications for Neonatal Care Beyond Klebsiella, researchers are considering combined vaccines that also target Acinetobacter and E. coli. If successful, a single maternal shot could drastically reduce newborn mortality, with estimates suggesting 80,000 to 400,000 lives saved annually. The team is currently refining the vaccine to cover a broader range of drug-resistant strains found globally. ## Sources covering this story - https://www.earth.com/science/vaccinating-moms-before-they-give-birth-saves-their-babies-from-dangerous-infections/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._